Added to YB: 2025-10-09
Pitch date: 2025-10-07
PSNL [bullish]
Personalis, Inc.
+26.53%
current return
Author Info
No bio for this author
Company Info
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Market Cap
$676.7M
Pitch Price
$7.69
Price Target
20.00 (+106%)
Dividend
N/A
EV/EBITDA
-9.03
P/E
-8.70
EV/Sales
8.22
Sector
Life Sciences Tools and Services
Category
growth
$PSNL: Cancer Diagnostic Company On the Cusp of a Dramatic Inflection
PSNL: Cancer recurrence blood test NeXT Personal detects 12-18mo earlier than CT/MRI, 98% retention, 59% volume growth Q/Q. Currently <1% revenue but Q4'25 Medicare reimbursement catalyst. Tempus partnership (owns 14.5%, filed to increase to 19.99%) provides distribution to 50% oncologists via one-click EMR integration. 6% market share = $100M EBIT by 2029 vs $500M EV today. Risk: reimbursement denial.
Read full article (16 min)